94 related articles for article (PubMed ID: 6572773)
1. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.
Preisler H; Barcos M; Reese P; Priore RL; Pothier L
Leuk Res; 1983; 7(1):67-75. PubMed ID: 6572773
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements.
Preisler HD; Priore R; Azarnia N; Barcos M; Raza A; Rakowski I; Vogler R; Winton EL; Browman G; Goldberg J
Br J Haematol; 1986 Aug; 63(4):625-36. PubMed ID: 3460626
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
[TBL] [Abstract][Full Text] [Related]
5. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
[TBL] [Abstract][Full Text] [Related]
6. Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
Browman G; Preisler H; Raza A; Syracuse K; Azarnia N; Benger A; Chervenick P; D'Arrigo P; Doeblin T; Goldberg J
Br J Haematol; 1989 Apr; 71(4):493-7. PubMed ID: 2653407
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Roberts MM; Juttner CA; To LB; Kimber RJ
Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
[TBL] [Abstract][Full Text] [Related]
8. Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside.
Tamura K; Preisler HD
Cancer; 1983 May; 51(10):1795-9. PubMed ID: 6572541
[TBL] [Abstract][Full Text] [Related]
9. [Prediction of resistance to remission induction in acute leukemia in adult].
Sampi K; Hayashi Y; Honda T; Hattori M
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1598-602. PubMed ID: 6575730
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Anticancer Res; 1985; 5(3):293-6. PubMed ID: 4015043
[TBL] [Abstract][Full Text] [Related]
11. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia.
Keating MJ; Smith TL; McCredie KB; Bodey GP; Hersh EM; Gutterman JU; Gehan E; Freireich EJ
Cancer; 1981 Jun; 47(12):2779-88. PubMed ID: 6942906
[TBL] [Abstract][Full Text] [Related]
12. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
[TBL] [Abstract][Full Text] [Related]
13. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sampi K; Honda T; Hayashi Y; Hattori M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory adult acute lymphocytic leukaemia and acute undifferentiated leukaemia with an anthracycline antibiotic and cytosine arabinoside.
Early AP; Preisler HD; Gottlieb AJ; Lanchant NA
Br J Haematol; 1981 Jul; 48(3):369-75. PubMed ID: 7259987
[TBL] [Abstract][Full Text] [Related]
15. Anthracyclines in the treatment of acute nonlymphocytic leukemias.
Boiron M; Jacquillat C; Marty M; Weil M; Gisselbrecht C
Cancer Treat Rep; 1981; 65 Suppl 4():73-6. PubMed ID: 6955013
[No Abstract] [Full Text] [Related]
16. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
[TBL] [Abstract][Full Text] [Related]
17. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
18. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
Preisler HD; Rustum Y; Priore RL
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup study.
Goldberg J; Grunwald H; Vogler WR; Winton E; Browman G; Walker I; Benger A; Miller KB; Rai K; Gottlieb AJ
Am J Hematol; 1985 Jun; 19(2):167-76. PubMed ID: 3890525
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
Takahashi I; Hara M; Uchida K; Takaoka K; Watanabe S; Lai M; Hamasaki K; Kohi F; Kitajima K; Kimura I; Adachi T; Yorimitsu S; Tokioka M; Sanada H
Acta Med Okayama; 1982 Feb; 36(1):77-80. PubMed ID: 6950658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
